GPM Growth Investors Inc. Sells 184 Shares of Stryker Co. (NYSE:SYK)

GPM Growth Investors Inc. decreased its position in shares of Stryker Co. (NYSE:SYK) by 0.8% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 22,705 shares of the medical technology company’s stock after selling 184 shares during the quarter. Stryker makes up 3.5% of GPM Growth Investors Inc.’s investment portfolio, making the stock its 11th largest position. GPM Growth Investors Inc.’s holdings in Stryker were worth $8,175,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Parnassus Investments LLC purchased a new stake in Stryker during the 3rd quarter worth about $762,798,000. Raymond James Financial Inc. purchased a new stake in Stryker during the 4th quarter worth about $353,394,000. Proficio Capital Partners LLC lifted its holdings in Stryker by 52,520.8% during the 4th quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock worth $214,660,000 after purchasing an additional 595,061 shares in the last quarter. RTW Investments LP purchased a new stake in Stryker during the 3rd quarter worth about $143,392,000. Finally, State Street Corp lifted its holdings in Stryker by 2.2% during the 3rd quarter. State Street Corp now owns 14,582,959 shares of the medical technology company’s stock worth $5,279,788,000 after purchasing an additional 316,404 shares in the last quarter. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In related news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now directly owns 3,642,075 shares in the company, valued at $1,428,567,498. The trade was a 5.24 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Price Performance

NYSE:SYK opened at $396.10 on Thursday. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a market capitalization of $151.14 billion, a price-to-earnings ratio of 51.04, a PEG ratio of 2.93 and a beta of 0.96. The business has a 50 day simple moving average of $381.96 and a 200-day simple moving average of $372.45.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the prior year, the company posted $3.46 EPS. Equities analysts forecast that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.85%. Stryker’s dividend payout ratio is presently 43.30%.

Wall Street Analyst Weigh In

Several analysts have weighed in on SYK shares. Stifel Nicolaus raised their price target on Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, January 29th. Wells Fargo & Company raised their price target on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Royal Bank of Canada raised their price target on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. JPMorgan Chase & Co. raised their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Morgan Stanley raised Stryker from an “equal weight” rating to an “overweight” rating and raised their price target for the company from $370.00 to $445.00 in a report on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Stryker has an average rating of “Moderate Buy” and a consensus target price of $422.15.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.